Email
Print
Post-Traumatic Stress Disorder Therapeutics Market - Forecast(2024 - 2030)
Post-Traumatic Stress Disorder Therapeutics Market Overview
The Post-Traumatic Stress Disorder Therapeutics Market size is estimated to reach $3.1 billion by 2028, growing at a CAGR of 4.5% during the forecast period 2023-2028. According to the Anxiety & Depression Association of America, anxiety disorders are the most common mental illnesses in the U.S., affecting 40 million adults (19.1% of the population) and older every year. Though benzodiazepines (BZDs) are typically utilized in the treatment of post-traumatic stress disorder (PTSD), no systematic review or meta-analysis has particularly inspected this treatment. The intensified focus on rehabilitation programs for wounded military personnel is set to drive the Post-Traumatic Stress Disorder Therapeutics Market. The increasing cases of depression and anxiety requiring antidepressants are set to propel the growth of the Post-traumatic Stress Disorder Therapeutics Industry during the forecast period 2023-2028. Post-traumatic Stress Disorder (PTSD) is a mental health condition that establishes succeeding a traumatic event characterized by obtrusive thoughts regarding the event, repeating distress/anxiety, flashback and evasion of identical situations. PTSD may be treated with the application of antidepressants. Monoamine oxidase A is one of the essential enzymes mediating the turnover of noradrenaline. Antipsychotics or second-generation antipsychotics are extensively utilized for PTSD. Beta-blockers like propranolol have been utilized to treat anxiety patients. This represents the Post-traumatic Stress Disorder Therapeutics Industry Outlook.
Post-Traumatic Stress Disorder Therapeutics Market Report Coverage
The “Post-Traumatic Stress Disorder
Therapeutics Market Report - Forecast (2023-2028)” by IndustryARC,
covers an in-depth analysis of the following segments in the Post-Traumatic Stress Disorder
Therapeutics Market.
Key Takeaways
- Geographically, North America (Post-Traumatic Stress Disorder Therapeutics market share) accounted for the highest revenue share in 2022 and it is poised to dominate the market over the period 2023-2028 owing to the principal contribution of the U.S. with depression cases requiring antidepressants in the North American region.
- The growth of the Post-Traumatic Stress Disorder Therapeutics Market is being driven by the rising rates of violence, accidents, cross-border tensions and occupational risks and accidents. However, the soaring cost of therapy involving antidepressants is one of the major factors hampering the growth of the Post-Traumatic Stress Disorder Therapeutics Market.
- Post-Traumatic Stress Disorder Therapeutics Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Post-Traumatic Stress Disorder Therapeutics Market report.
Post-traumatic Stress Disorder Therapeutics Market: Market Share (%) by Region, 2022
For More Details on This Report - Request for Sample
Post-Traumatic Stress Disorder Therapeutics Market Segment Analysis - by Product
The Post-traumatic Stress Disorder Therapeutics Market, based on products, can be further segmented into Antidepressants, Anxiolytics and Others. The Antidepressants segment held the largest share of the Post-Traumatic Stress Disorder Therapeutics Market in 2022. This growth is fueled by the surging application of antidepressants for the treatment of post-traumatic stress disorder. SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) are the more common kinds of antidepressant medicines. The capability of antidepressants to assist symptoms of anxiety and depression is further propelling the growth of the Antidepressants segment. Furthermore, the Antidepressants segment is estimated to grow at the fastest CAGR of 5.3% during the forecast period 2023-2028. It is due to the soaring application of selective serotonin reuptake inhibitor (SSRI) medications sertraline (Zoloft) and paroxetine (Paxil) which are approved by the U.S. Food and Drug Administration (FDA) for PTSD treatment.
Post-Traumatic
Stress Disorder Therapeutics Market Segment Analysis - by Patient
The Post-Traumatic Stress Disorder Therapeutics Market, based on patients, can be further segmented into Adults, Children and Others. The Adults Segment held the largest share of the Post-Traumatic Stress Disorder Therapeutics Market in 2022. This growth is driven by the increasing prevalence of post-traumatic stress disorder (PTSD) among mature grown-ups across the world. Certain causes of PTSD among adults may be traumatic events in life like accidents or natural disasters and severe medical conditions. The soaring count of PTSD cases among women, with women being three times more likely to develop the ailment annually, is further propelling the growth of this segment. Furthermore, the Adult segment is estimated to grow at the fastest CAGR of 5.5% during the forecast period 2023-2028, owing to the enormous count of novel diagnoses of PTSD amidst deployed troops.
Post-Traumatic Stress Disorder Therapeutics Market Segment Analysis - by Geography
North America (Post-Traumatic Stress Disorder Therapeutics Market) dominated the largest Post-Traumatic Stress Disorder Therapeutics Market with a 41% share of the overall market in 2022. The growth of this region is owing to the rising pervasiveness of post-traumatic stress disorder (PTSD) among Americans in the North American region. The surging application of beta-blockers like propranolol for PTSD is further propelling the growth of the Post-traumatic Stress Disorder Therapeutics Industry, thereby contributing to the Post-traumatic Stress Disorder Therapeutics Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is fueled by factors like increasing cases of PTSD among South-Asian men requiring beta-blockers in the Asia-Pacific region. The rising cases of depression and trauma are further fueling the progress of the Post-Traumatic Stress Disorder Therapeutics Market in the Asia-Pacific region.
Post-Traumatic Stress Disorder Therapeutics Market Drivers
Increasing Predominance of Post-traumatic Stress Disorder:
As per the website: policylab.us, Post-traumatic Stress Disorder (PTSD) influences 3.5% of the mature grown-up populace in the U.S., which is approximately 8 million Americans. Investigations have checked the prevalence of PTSD among high-risk children who have endured particular traumatic events like abuse or natural disasters. Research demonstrates that children exposed to traumatic incidents may have a greater prevalence of PTSD than mature grown-ups in the general population. The increasing predominance of Post-traumatic Stress Disorder is therefore fueling the growth of the Post-Traumatic Stress Disorder Therapeutics Market during the forecast period 2023-2028.
Surging Applications of Antipsychotics or Second generation Antipsychotics:
The National Comorbidity Survey (NCS) demonstrated that 79 percent of women and 88 percent of men with PTSD had at least one other psychiatric diagnosis. Antipsychotics have also been examined in people with a basic diagnosis of PTSD. Antipsychotics or Second Generation Antipsychotics specifically perform by obstructing the excitatory action of dopamine and serotonin, chemicals (neurotransmitters) discharged by nerve cells (neurons) to carry nerve signals. The two best-investigated antipsychotics treatment for PTSD are Risperidone and Olanzapine. The surging applications of Antipsychotics or Second Generation Antipsychotics are therefore driving the growth of the Post-traumatic Stress Disorder Therapeutics Industry, thereby contributing to the Post-traumatic Stress Disorder Therapeutics Industry Outlook during the forecast period 2023-2028.
Post-Traumatic Stress Disorder Therapeutics Market Challenges
The Ineffectiveness of Benzodiazepines for PTSD Treatment and Prevention:
Though benzodiazepines are prescribed to 30% to 74% of patients with PTSD, there is little literature focusing on the application of benzodiazepines to avert or treat PTSD. Studies have been organized on all relevant articles utilizing diversified electronic databases and independently abstracted information from investigations calculating PTSD outcomes in patients utilizing benzodiazepines. Results of the investigations conducted indicated that benzodiazepines are inefficient for PTSD treatment and avoidance and hazards linked with their application tend to outweigh possible short-term advantages. These issues are thus hampering the growth of the Post-Traumatic Stress Disorder Therapeutics Market.
Post-Traumatic Stress Disorder Therapeutics Industry Outlook
Novel product launches, mergers and acquisitions, collaborations, partnerships, agreements, geographical expansions and R&D activities are key strategies adopted by players in the Post-Traumatic Stress Disorder Therapeutics Market. The top 10 companies in the Post-Traumatic Stress Disorder Therapeutics Market include:
- AstraZeneca Plc
- Azevan Pharmaceuticals, Inc.
- Bionomics Ltd.
- Eli Lilly and Company
- GlaxoSmithKline Plc
- H. Lund beck AS
- Pfizer Inc.
- Lupin Limited,
- Aurobindo Pharma Limited
- Otsuka Pharmaceutical Co. Ltd.
Recent Developments
- In December 2021, Eli Lilly and Company and Regor Therapeutics Group entered into a multi-year research collaboration and licensing agreement. This was to find, establish and commercialize new therapies. The therapies were for metabolic ailments.
- In January 2021, Eli Lilly and Company declared the favorable completion of its acquisition of Prevail Therapeutics Inc. The acquisition enables them to develop a novel modality for drug discovery and development at Lilly. This boosts Lilly's research efforts.
- In October 2020, Eli Lilly and Company declared a definitive agreement to gain Disarm Therapeutics. Disarm has found new, effective SARM1 inhibitors. It is promoting them in preclinical development.
Relevant Reports:
Report
Code: HCR 0904
Report Code: HCR 0611
Report Code: HCR 0277
For more Lifesciences and Healthcare Market reports, please click here